Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 vaccine - Castlevax

Next Previous
Drug Profile

COVID-19 vaccine - Castlevax

Alternative Names: AVX/COVID-12 (Patria) Vaccine; AVX/COVID-12 vaccine; AVX/COVID-12-HEXAPRO; CVAX-01; Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine; NDV-HXP-S vaccine; Patria; Recombinant NDV Vectored Vaccine for SARS-CoV-2; Recombinant NDV Vectored Vaccine for SARS-CoV-2 - Avimex; Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2; Recombinant SARS-CoV-2 vaccine - Avimex; Sars-CoV-2 vaccine - Avimex

Latest Information Update: 12 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CastleVax
  • Developer Avimex; CastleVax
  • Class COVID-19 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 05 Nov 2025 Registered for COVID-2019 infections (Prevention) in Mexico (IM)
  • 05 Nov 2025 Registered for COVID-2019 infections (Prevention) in Thailand (IM)
  • 05 Nov 2025 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by Castlevax

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top